Johnson&Johnson CEO: Currently has no intention of producing weight loss drugs and focuses on expanding into fields such as neurology and oncology
我放心你带套猛
发表于 2023-12-6 09:51:55
255
0
0
Johnson&Johnson CEO Joaquin Duato stated at the company's Investor Day event on December 5th that the company currently has no plans to produce weight loss pills due to the intense competition in the market.
Du Anqing stated that Johnson&Johnson is focusing on expanding widely in fields such as neurology and oncology. Du Anqing said, "If Johnson&Johnson has the opportunity to stand out in the weight loss drug market through assets that complement the company's business, it may reconsider."
CandyLake.com 系信息发布平台，仅提供信息存储空间服务。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
转播
猜你喜欢
- Kenvue, Global layoffs: Johnson&Johnson plans to clear its holdings, raise prices to sustain sales, and it is difficult to maintain sales
- Johnson&Johnson plans to acquire biotech company Proteology for $850 million
- Is Johnson&Johnson clearing Kenvue shares and withdrawing from the skincare and beauty industry a win-win situation or a last resort?
- Qiangsheng subsidiary responds to "shortage of focus in Daduo": the company faces supply pressure and challenges due to a significant increase in market demand
- Lilly: We have applied to the FDA for the weight loss drug Zepbound to treat sleep apnea, and it is expected to be approved as early as the end of the year
- Johnson&Johnson appoints Zhou Mintao as President of Medical Technology China
- Johnson&Johnson China completes business changes, with Song Weiqun stepping down as chairman
- Johnson&Johnson China CEO Song Weiqun steps down as Chairman of Johnson&Johnson China
- Novo Nordisk reaches settlement with Mylan Pharmaceuticals over patent dispute over weight loss drug Ozempic and Wegovy
- Citigroup raises Johnson&Johnson's target price from $180 to $185
-
【英偉達の需要が高すぎる？SKハイニックス：黄仁勲がHBM 4チップの6カ月前納入を要求！】SKハイニックスの崔泰源（チェ・テウォン）会長は月曜日、インビダーの黄仁勲（ファン・インフン）CEOが同社の次世代高帯域 ...- 琳271
- 前天 17:54
- 支持
- 反对
- 回复
- 收藏
-
ファイザーが前立腺がんを治療する革新薬テゼナ& ;reg;（TALZENNA®，一般名：トルエンスルホン酸タラゾールパーリカプセル）は2024年10月29日に国家薬品監督管理局（NMPA）の承認を得て、HRR遺伝子突然変異 ...- 什么大师特
- 昨天 17:41
- 支持
- 反对
- 回复
- 收藏
-
南方財経は11月5日、中央テレビのニュースによると、現地時間11月5日、米ボーイング社のストライキ労働者が59%の投票結果で新たな賃金協定を受け入れ、7週間にわたるストライキを終えた。ストライキ労働者は11月12 ...- Dubssgshbsbdhd
- 昨天 16:27
- 支持
- 反对
- 回复
- 收藏
-
【マスクはテスラが携帯電話を作ることに応えた：作れるが作らないアップルとグーグルが悪さをしない限り】現地時間11月5日、有名ポッドキャストのジョローガン氏のインタビューに応じ、「携帯電話を作るのは私たち ...- 波大老师
- 昨天 14:41
- 支持
- 反对
- 回复
- 收藏
